Research Archives – Page 2 of 3 – Treatment Action Group

New HIV Prevention Research Fact Sheet

October 26, 2021
Dorrit Walsh

HIV prevention research continues to rapidly evolve. The availability of pre-exposure prophylaxis (PrEP) has necessitated the development of new approaches to testing the efficacy of additional biomedical HIV prevention options. This handout was developed in collaboration with the Black AIDS…

Broadly Neutralizing Antibodies for HIV Prevention Fact Sheet

October 26, 2021
Dorrit Walsh

HIV-specific broadly neutralizing antibodies (bNAbs) could have a role in treating, preventing, or even curing HIV. Some HIV-specific bNAbs are already being tested in clinical trials, both for prevention and treatment. This handout was developed in collaboration with the Black…

Substantial Public Investments in GeneXpert Underscore Need for Affordable Pricing

August 27, 2021
Dorrit Walsh

TAG’s comprehensive analysis found that the public invested at least $252 million USD in the research and development of GeneXpert diagnostic technology, which stands in stark contrast to the lack of affordable pricing and favorable service and maintenance terms from the diagnostics company Cepheid.

Comments to NIH Leadership Regarding the Proposed Advanced Research Projects Agency for Health

August 5, 2021
Dorrit Walsh

In response to the Biden administration's intention to create a new research agency under the NIH called the Advanced Research Projects Agency for Health (ARPA-H), TAG and AVAC were invited to present remarks and guidance on the behalf of the Federal AIDS Policy Partnership and Research Work Group (RWG).

Investment in HIV Research Profoundly Benefits the COVID-19 Response

December 2, 2020
Dorrit Walsh

This policy brief discusses how investment in HIV research has profoundly benefitted the COVID-19 response, and advocates that continued financial support for HIV science can both ensure progress on COVID-19 and avoid losing ground—and lives—in the fight to end the HIV epidemic.

Treatment Action Group Statement on New HIV Remission Case Report at AIDS2020

July 8, 2020
Dorrit Walsh

Yesterday, a widely reported presentation by Ricardo Diaz at the ongoing virtual International AIDS Conference (AIDS2020) disclosed that one out of 30 total participants in an HIV cure-related research trial conducted in Brazil has not experienced an HIV viral load rebound for a little over a year (64.7 weeks) after interrupting antiretroviral therapy (ART).

AVAC and TAG Statement on Ethical Conduct of SARS-CoV-2 Vaccine Challenge Studies

May 7, 2020
Dorrit Walsh

The COVID-19 pandemic is a global health emergency that may demand new, safe, and expedited ways of conducting ethical research to find the solutions we need, including a safe and effective vaccine.

Treatment Action Group and the PrEP4All Collaboration Respond to Reported Remdesivir Results for COVID-19

April 30, 2020
Dorrit Walsh

Treatment Action Group (TAG) and the PrEP4All Collaboration welcome results from randomized controlled trials of therapies for COVID-19, but are seriously concerned about claims that data from a National Institutes of Allergy and Infectious Diseases (NIAID) study of the Gilead drug remdesivir...

Treatment Action Group Statement on BCG Vaccine and COVID-19

April 9, 2020
Dorrit Walsh

Treatment Action Group (TAG) cautions that widespread media reports that the baccille Calmette–Guérin (BCG) vaccine may be protective against COVID-19 need to be read with caution.

Responding to Difficult-to-Treat HCV Subtypes Prevalent in Sub-Saharan Africa

February 17, 2020
Dorrit Walsh

An issue brief that discusses the recent discovery of HCV subtypes that show resistance to direct-acting antiretroviral (DAA) regimens that are responsive to treatments in people expressing the 1a/1b subtype.